NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Stock Information for ADDvantage Technologies Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ADDvantage Technologies Group Inc.

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
Life Sciences Investor Forum Agenda Announced for November 14th
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.